Yahoo Finance • 24 days ago
SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced The Lancet Oncology published a study highlighting the performance... Full story
Yahoo Finance • 25 days ago
SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six prospective controll... Full story
Yahoo Finance • 26 days ago
Company Logo Liquid Biopsy MarketLiquid Biopsy Market Dublin, Sept. 02, 2025 (GLOBE NEWSWIRE) -- The "Liquid Biopsy Market by Product & Service (Kits, Instruments), Circulating Biomarker (ctDNA, cfDNA, CTC), Technology (NGS, PCR), Applic... Full story
Yahoo Finance • last month
SALT LAKE CITY, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare confer... Full story
Yahoo Finance • last month
[Diagnosis testing of patients.] Natali_Mis/iStock via Getty Images ANGLE plc (OTCQX:ANPCF [https://seekingalpha.com/symbol/ANPCF]) and Myriad Genetics (NASDAQ:MYGN [https://seekingalpha.com/symbol/MYGN]) have announced a new partnership... Full story
Yahoo Finance • last month
* Ben Wheeler appointed chief financial officer of Myriad Genetics (NASDAQ:MYGN [https://seekingalpha.com/symbol/MYGN]), effective August 16, 2025. * Wheeler has been with the company since 2011, most recently serving as CFO of Operat... Full story
Yahoo Finance • last month
SALT LAKE CITY, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Ben Wheeler has been promoted to Chief Financial Officer, effe... Full story
Yahoo Finance • 2 months ago
SALT LAKE CITY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today released findings from its latest Cancer Risk Survey that uncover a striking... Full story
Yahoo Finance • 2 months ago
Curious about what's happening in today's session? Check out the latest stock movements and price changes. [topmovers] TOP GAINERS TICKER CHANGE COMMENT SGBX [https://www.chartmill.com/stock/quote/SGBX/profile] 86.14% SAF... Full story
Yahoo Finance • 2 months ago
Wondering how the US markets performed in the middle of the day on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis. [topmovers] TOP GAINERS TICKER CHANGE COMMENT GO [https://www.cha... Full story
Yahoo Finance • 2 months ago
Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps. [gap] GAP UP STOCKS TICKER CHANGE COMMENT SGBX [https://www.chartmill.com/stock/quote/SGBX... Full story
Yahoo Finance • 2 months ago
As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. [premarket] TODAY'S PRE-MARKET GAINERS TICKER CHANGE COMME... Full story
Yahoo Finance • 2 months ago
Earnings Call Insights: Myriad Genetics (MYGN) Q2 2025 MANAGEMENT VIEW * President and CEO Samraat S. Raha opened by stating he remains confident in Myriad's significant potential, emphasizing, "I'm excited about the journey we're on t... Full story
Yahoo Finance • 2 months ago
Key Points Revenue (GAAP) exceeded analyst estimates by 5.6%, with strong pricing and product mix lifting the topline. Reported a non-cash impairment charge of $316.7 million (GAAP), leading to a large net loss despite adjusted EPS of $0.... Full story
Yahoo Finance • 2 months ago
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. [postmarket] GAINERS TICKER CHANGE COMMENT... Full story
Yahoo Finance • 2 months ago
Myriad Genetics Inc (NASDAQ:MYGN) presented its second quarter 2025 earnings results on August 5, showing signs of recovery after a challenging first quarter. The genetic testing company reported modest revenue growth and raised its full-... Full story
Yahoo Finance • 2 months ago
* Myriad Genetics (NASDAQ:MYGN [https://seekingalpha.com/symbol/MYGN]) announced on Thursday it has closed a five-year senior secured term loan credit facility providing up to $200 million of capital from OrbiMed. * The facility includ... Full story
Yahoo Finance • 2 months ago
SALT LAKE CITY, July 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2025 earnings conference call at 4:30pm ET on Tuesday,... Full story
Yahoo Finance • 2 months ago
What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 3.8% in the afternoon session after weakness in the healthcare sector became pronounced following a poor sales report from a key competitor. The negative... Full story
Yahoo Finance • 2 months ago
Investing.com - Piper Sandler has identified potential buying opportunities in dislocated Life Science Tools & Labs stocks, particularly highlighting Neogenomics (NASDAQ:NEO), Myriad Genetics (NASDAQ:MYGN), and Cytek Biosciences (NASDA... Full story